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A key region of molecular speciﬁcity orchestrates unique
ephrin-B1 utilization by Cedar virus
Rhys Pryce1,* , Kristopher Azarm2,* , Ilona Rissanen1,3, Karl Harlos1, Thomas A Bowden1 , Benhur Lee2,4
The emergent zoonotic henipaviruses, Hendra, and Nipah are
responsible for frequent and fatal disease outbreaks in domestic
animals and humans. Speciﬁcity of henipavirus attachment gly-
coproteins (G) for highly species-conserved ephrin ligands un-
derpins their broad host range and is associated with systemic
and neurological disease pathologies. Here, we demonstrate that
Cedar virus (CedV)—a related henipavirus that is ostensibly
nonpathogenic—possesses an idiosyncratic entry receptor rep-
ertoire that includes the common henipaviral receptor, ephrin-
B2, but, distinct from pathogenic henipaviruses, does not include
ephrin-B3. Uniquely among known henipaviruses, CedV can use
ephrin-B1 for cellular entry. Structural analyses of CedV-G reveal
a key region of molecular speciﬁcity that directs ephrin-B1 utili-
zation, while preserving a universal mode of ephrin-B2 recognition.
The structural and functional insights presented uncover diversity
within the known henipavirus receptor repertoire and suggest that
only modest structural changes may be required to modulate re-
ceptor speciﬁcities within this group of lethal human pathogens.
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Introduction
The prototypic henipaviruses (HNVs), Hendra virus (HeV), and Nipah
(NiV) virus are biosafety level four (BSL4) pathogens responsible for
severe human disease that is associated with rapid onset and case
fatality rates that can exceed 90% (1, 2, 3). In addition, the extreme
disease pathologies, absence of a licensed vaccine, paucity of
medical intervention options, and zoonotic potential delineate
HNVs as an acute and persistent threat to global biosecurity,
economy, and health (4). Although zoonotic spillover is typically
associated with transmission from chiropteran reservoirs, or via
infection of domestic animal intermediates, such as pigs and
horses, transmission is not restricted to cross-species spillover
events. Direct human-to-human spread is frequent and highlights
the pandemic potential of HNVs (5, 6, 7).
Serological studies suggest that HNVs occupy a broad geo-
graphic range coincident with, but not restricted to, the home range
of reservoir bat species of the order Chiroptera (8, 9). Although there
is evidence for the existence and spillover of previously unchar-
acterized HNVs in Africa and Central- and South-America (10, 11, 12,
13, 14, 15), an accurate appraisal of the human impact of such HNVs
is likely hindered by the spectrum of clinical outcomes inherent to
diverse HNV species (16). Indeed, the indirect association of a novel
HNV, Mójiang virus (MojV), with the death of three miners in China
highlights the potential of non-chiropteran hosts as reservoirs of
lethal HNVs (17). The putatively rat-borne MojV uses a structurally
divergent attachment glycoprotein to mediate a distinct host-cell
entry pathway (18). The continued discovery and emergence of
novel HNV species underscores the indeterminate global health
threat that they pose (4, 12).
Cedar virus (CedV) is a Henipavirus species isolated from the
excreta of Pteropus bat colonies in Queensland, Australia (19).
Although geographically, genetically, and serologically related to
the highly virulent prototypic HNVs, CedV is apathogenic in small
animal models (19). The stark disparity in HNV pathogenesis has
been attributed, in part, to the lack of an otherwise conserved RNA-
editing site and the alternate reading frame coding capacity for
accessory proteins within the CedV phosphoprotein (P) gene (19). In
NiV and HeV, RNA editing facilitates the production of the accessory
proteins, V and W, which are capable of antagonizing the IFN re-
sponse. The absence of these immunomodulatory accessory pro-
teins in CedV results in a failure to mitigate the antiviral effects of
the type I IFN response and likely represents a critical factor in
determining infection outcomes (20).
The single-stranded negative-sense RNA genome of HNVs en-
codes two surface glycoproteins: the receptor-binding glycoprotein
(G) and the type I viral fusion protein (F), which work in concert to
orchestrate cellular entry (21, 22, 23). Binding of the HNV-G to cell
surface receptors belonging to the ephrin ligand family initiates
pH-independent activation of F, triggering a fusion cascade that
results in the ultimate merger of viral and cellular membranes.
HNV-G proteins comprise a short N-terminal cytosolic region,
single-pass transmembrane domain, oligomerization-mediating and
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fusion-activating stalk region, and C-terminal receptor-binding
β-propeller domain (24, 25). Orthologs of the two established HNV
receptors, ephrin-B2, and ephrin-B3 are extremely well conserved
across numerous reservoir and vector species and are recognized
by all known ephrin-tropic HNV-G proteins with a conserved
binding mode (26, 27, 28). Utilization of ephrins as cellular entry
receptors is fundamental to the broad cell type and species tropism
of HNVs and underscores key features of HNV zoonosis and
pathogenesis (29, 30).
Despite lacking canonical type I IFN antagonists (V andW) (19, 20),
CedV does possess a functional C accessory protein, the coun-
terparts of which exhibit type I IFN antagonism in NiV (31, 32, 33, 34).
Furthermore, CedV is able to establish a productive, albeit self-
limiting, infection in Syrian hamsters that is more robust when
inoculated via the intranasal versus intraperitoneal route (20).
Together, these observations suggest that the identity of cellular
receptors for CedV and the efﬁciency with which they are used may
constitute additional modiﬁers of pathogenicity. Here, we sought to
delineate the functional entry receptor repertoire of CedV and
elucidate the molecular determinants of receptor speciﬁcity. In our
integrated structural and functional analysis, we demonstrate that
in addition to using the common HNV receptor, ephrin-B2, CedV
uses ephrin-B1, a receptor with no precedent of HNV usage.
Structural analyses reveal that whereas CedV-G conforms to the
establishedmode of HNV-Gmediated ephrin receptor engagement,
subtle structural features of the glycoprotein contribute to its
unique ephrin ligand speciﬁcity. These data highlight functional
diversity amongst HNV-G proteins and provide mechanistic insight
into potential modulators of HNV pathobiology.
Results
The crystal structure of CedV-G reveals a conserved
receptor-binding architecture
Although reported to use the common entry receptor, ephrin-B2
(19, 35), CedV-G is genetically distinct from all characterized ephrin-
tropic HNVs (26%, 28%, and 31% identical to GhV-G [Ghana virus],
HeV-G, and NiV-G, respectively) (27). To assess the extent to which
this sequence divergence is reﬂected at a structural level, we
determined the crystal structure of the CedV-G receptor-binding
domain to 2.78-A˚ resolution. Two essentially identical molecules of
CedV-G were present within the crystallographic asymmetric unit
(a.s.u.) (root-mean-square deviation [RMSD] 0.3 A˚ across 416
equivalent Cα atoms), with the only region of notable structural
variation localizing to the β6-S2–S3 loop (Fig 1A). Electron density
permitted modelling of the entire receptor-binding domain of
CedV-G included in the crystallized construct (residues K209–C622)
(Fig 1B).
The receptor-binding domain of CedV-G adopts the canonical
six-bladed β-propeller fold used by known HNVs (18, 26, 39, 40, 41).
Each of the six blades (β1–β6) comprise four antiparallel β-strands
that assemble in a toroidal arrangement and form a central
depression at the membrane-distal “top” surface of the mole-
cule (Fig 1A). Like the prototypic HNVs, the β2 and β3 blades are
decorated with extended loops that form three short 310 helical
segments (η1–η3) and three α-helices (α1–α3). Eight disulphide
bonds stabilize the fold, seven of which are conserved amongst
other HNV-G proteins (Fig S1), indicative of structural importance in
stabilizing the β-propeller. The additional disulphide linkage in
CedV-G (C310–C376) links blades β2 and β3 at the base of the
molecule.
The receptor-binding domain of CedV-G possesses eight N-linked
glycosylation sequons, threemore than the prototypic HNV-Gs. Electron
density corresponding to an asparagine-linked N-acetylglucosamine
moiety was observed at seven sites (Figs 1A and B, and S2A). The
distribution of glycan sites within CedV-G is consistent with previous
studies that implicate the glycan-free β1 and β6 blades in the for-
mation of a homodimeric interface as part of the higher order as-
sembly of virion-displayed HNV-Gs (40, 42, 43). Only one of these
sequons, N502CedV, is conserved with HeV-G (N481HeV) and NiV-G
(N481NiV) at the primary sequence level. Interestingly, glycosylation
at N481HeV/NiV has been shown to modulate fusion activation, sug-
gestive that N502CedV may play a similar role (44). The otherwise
heterogeneous distribution of N-linked glycosylation sequons sug-
gests an absence of functional constraints that would dictate the
absolute position of glycan sites across extant HNV-G proteins.
Comparison of CedV-G with unliganded HeV-G (Protein Data
Bank [PDB] accession code 2X9M) and NiV-G (PDB: 2VWD) reveals
considerable structural similarity within the β-propeller scaffold
(Cα atom RMSD of 1.7 A˚ over 385 residues and 1.6 A˚ over 371 residues)
(Fig 1C), despite substantial primary sequence divergence (Fig S1).
Concomitant with genetic proximity, structure-based phylogenetic
classiﬁcation places CedV-G in a cluster of ephrin-tropic HNV-G
proteins, closer to the Asiatic prototype viruses HeV-G and NiV-G
than the African GhV-G (Fig 1D). Such structure-based phylogenetic
classiﬁcation has demonstrable utility in deﬁning clusters of viral
receptor-binding glycoproteins that use common receptors (18, 45)
and, when applied to CedV-G, supports utilization of ephrins.
Whereas core secondary structure elements of the β-propeller
scaffold are similar, loop regions exhibit substantial structural
differences. Interestingly, structural conservation within the apical
loops can be broadly divided into two spatially continuous sec-
tions: blades β1–3 are structurally variable and β4–β6 exhibit
markedly lower RMSD values (average Cα RMSD of 1.8 and 1.0 A˚,
respectively) (Fig 1C). ~70% (28/40) of the NiV-G and HeV-G resi-
dues that participate in ephrin-B2 recognition are contributed by
the structurally conserved β4–β6 blades (Fig S1), suggestive that
local structure is constrained by a requirement to maintain ephrin
binding.
CedV-G binds both ephrin-B1 and ephrin-B2
Given the extent and distribution of structural similarities between
CedV-G and ephrin-tropic HNVs, we hypothesized that CedV-G likely
uses high-afﬁnity ephrin binding to mediate cellular entry. To this
end, we examined the binding of soluble ephrins to cell surface
expressed HNV-G proteins (Fig 2A). Human embryonic kidney (HEK)
293T cells were transfected with HA-tagged HNV-G glycoproteins
(NiV-G, HeV-G, GhV-G, and CedV-G) and titrated against soluble Fc-
tagged human B-type ephrins (ephrin-B1–Fc, ephrin-B2–Fc, and
ephrin-B3–Fc) to obtain apparent dissociation constants (Kd). In
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Figure 1. The CedV-G β-propeller exhibits regions that are structurally conservedwith ephrin-tropic HNV-Gs suggestive of a preservedmode of receptor recognition.
(A) The structure of CedV-G is displayed as a cartoon colored from the N- to C terminus (blue to red), with the termini shown as spheres. The approximate extent of each
of the six “blades” of the β-propeller is delineated by a colored triangle, labelled β1–β6. The region of highest variability (β6-S2–S3 loop) between the a.s.u. copies
(molecule “A” and “B”) of the protein is shown with an inset panel (dashed line). Molecule A is shown in rainbow and the β6-S2–S3 loop of molecule B is shown in black. The
protein is displayed in a “top” view (left) and rotated 50° to reveal a side view on which the putative receptor-binding site is depicted with a dashed line. N-linked
glycans are shown as sticks and colored according to constituent elements. Asparagine residues from all eight N-linked glycosylation sequons are displayed as sticks. The
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agreement with previous studies (26, 36, 46, 47), NiV-G bound both
ephrin-B2–Fc and ephrin-B3–Fc with nanomolar afﬁnities (Kd = 1.4 and
2.0 nM, respectively), and binding of HeV-G to ephrin-B3–Fc was
approximately ﬁvefold weaker than to ephrin-B2–Fc (Kd = 5.3 and 0.86
nM, respectively) (36, 48). Unlike the prototypic HNV-Gs, GhV-G
exhibited no detectable interaction with ephrin-B3–Fc but bound
strongly to ephrin-B2–Fc (Kd = 0.82 nM) (26). Consistent with our
structure-based hypothesis, CedV-G exhibited high afﬁnity binding to
ephrin-B2–Fc (Kd = 2.3 nM) but, similar to GhV-G, lacked a titratable
interaction with ephrin-B3–Fc. Unexpectedly, we also detected a
nanomolar–afﬁnity interaction between CedV-G and ephrin-B1–Fc
(Kd = 4.0 nM), a receptor with no precedent of HNV-G binding.
As ephrin-B1 binding was unexpected, we sought to determine
whether the high-afﬁnity interactions between CedV-G and both
ephrin-B1 and ephrin-B2 have relevance to viral entry. We ﬁrst
tested whether cognate soluble ephrin-B ligands could inhibit
the entry of HNV pseudotyped particles (HNVpp) into a mammalian
cell type that is permissive to HNV infection, Vero-CCL81 cells.
HNV envelope glycoproteins (F and G) were pseudotyped onto a
recombinant vesicular stomatitis virus (VSV) expressing a Renilla
Luciferase (rLuc) reporter gene in place of its endogenous envelope
glycoproteins (VSV-ΔG-rLuc). Such VSV-based HNVpp, when used as a
surrogate in antibody neutralization assays, have been validated by
the Centres for Disease Control and Prevention (CDC; reference 49) as
equivalent to the gold standard plaque reduction neutralization titer
assay using live HNV (11, 26, 46, 47). We then infected Vero-CCL81 cells
with HNVpp in the presence of varying concentrations of soluble
ephrin-B–Fc (Fig 2B). To ensure the veracity of our results, we used a
ﬁxed quantity of HNVpp pre-determined to give rLuc activity within the
linear dynamic range established for this reporter assay (11). Entry of
both NiVpp and HeVpp was inhibited by soluble ephrin-B2–Fc and
ephrin-B3–Fc but not ephrin-B1–Fc (Fig 2B, top). In contrast, CedVpp
entry was inhibited by soluble ephrin-B1–Fc and ephrin-B2–Fc, but not
ephrin-B3–Fc, whereas GhVpp was only inhibited by ephrin-B2–Fc (Fig
2B, bottom). These entry inhibition data are consistent with the
binding data (Fig 2A) and implicate both ephrin-B1 and ephrin-B2 as
receptors for CedV entry.
Ephrin-B1 and ephrin-B2 support CedV entry
To examine whether ephrin-B1 and ephrin-B2 can function as bona
ﬁde receptors for CedV entry, we infected ephrin-negative CHO-
pgsA745 cells, engineered to stably express ephrin-B1, -B2, or -B3
(CHO-B1, CHO-B2, and CHO-B3) (46, 47), with CedVpp or NiVpp.
Across several logs of viral input, CedVpp was able to infect both
CHO-B1 and CHO-B2 cells, but not CHO-B3 cells (Fig 3). Furthermore,
NiVpp robustly infected CHO-B2 and CHO-B3 cells but exhibited
markedly reduced entry (1,000-fold decrease in relative light unit)
into CHO-B1 cells, as has been previously observed (46). Thus,
ectopic expression of either ephrin-B1 or ephrin-B2 is sufﬁcient to
permit entry of CedVpp into an otherwise non-permissive cell type
(CHO-parental) (Fig 3A–C). Furthermore, CedVpp entry into CHO-B2
cells yielded moderate but consistently higher entry levels than
CHO-B1 cells (Fig 3C versus 3B), corroborating the afﬁnity-binding
(Fig 2A) and ephrin inhibition (Fig 2B) data, indicating that CedV-G
uses ephrin-B2 more efﬁciently than ephrin-B1.
Intriguingly, although both NiV-G and CedV-G exhibit nanomolar
afﬁnity binding to ephrin-B2 (Fig 2A), approximately an order of
magnitude more CedVpp viral genomes (per mL) were required to
achieve entry levels equivalent to NiVpp on CHO-B2 cells (Fig 3C). To
eliminate the possibility that NiV glycoproteins are better in-
corporated into VSV pseudotypes than the CedV equivalents, we
performed a western blot analysis, which demonstrated that nei-
ther CedV-G nor the fusion-competent cleavage product of CedV-F
(CedV-F1) were signiﬁcantly less incorporated (Fig S3A). Thus, the
reduced infectivity of CedVpp is likely a consequence of intrinsically
reduced fusogenicity of CedV-F/G compared to NiV-F/G, as evi-
denced by smaller and fewer syncytia formed by CedV-F/G relative
to both NiV-F/G andHeV-F/G, in highly permissive U87 glioblastoma
cells (Fig S3B). Despite the lower fusogenicity of CedV-F/G and
reduced infectivity, relative to NiVpp on CHO-B2 cells, CedVpp in-
fection was consistently 1–2 logs higher than NiVpp on CHO-B1 cells
(Fig 3B). Only at the highest level of viral inoculums (>109 viral
genomes/ml) did NiVpp exhibit very low levels of infectivity on
CHO-B1 cells. Altogether, these data indicate that CedV is unique
amongst known HNVs in its ability to speciﬁcally use both ephrin-B1
and ephrin-B2 for cellular entry.
Ephrin-B1 supports CedV entry into physiologically relevant
primary cells
As endothelial cells constitute the primary targets of HNV infection
in vivo (50, 51, 52), we used primary HUVECs to investigate the
importance of ephrin-B1 as a functional entry receptor for CedV in a
putative dimerization interface contributed by the β1 and β6 blades is denoted with a solid black line. (B) Domain organization and salient features of CedV-G. The
attachment-mediating β-propeller domain, transmembrane, and intra-virion regions are labelled. Putative N-linked glycosylation sites are displayed as pins, with sites
occupied in the crystal structure colored black. (A) The extent of the crystallized construct is colored as a rainbow as in (A). (C) Structural comparison of CedV-G and
unliganded NiV-G (PDB accession code: 2VWD). Because of the high level of structural similarity between NiV-G and HeV-G (36), an HeV-G comparison is omitted for
clarity. RMSD between aligned Cα residues is depicted by both color (in a gradient from blue to red with increased RMSD) and tube width (thin to thick with increased
RMSD). Residues that failed to align or exhibited RMSDs greater than 3 Ε were assigned values of 3 Ε. The average RMSD across each blade is displayed next to the
respective blade label and the more structurally conserved region of the molecule (β4–β6) is indicated with a dashed line. The NiV-G–ephrin-B2 interface is displayed
as a grey shadow superposed onto the structure of CedV-G. (D) Structure-based phylogenetic analysis of paramyxovirus receptor-binding proteins places CedV-G amongst
ephrin-using HNV-G proteins. Pairwise distance matrices were calculated with Structural Homology Program (37) and plotted with PHYLIP (38), using the structures of
unliganded receptor-binding glycoproteins, where available. The corresponding structures are shown in surface representation with previously characterized
receptor-binding surfaces shown in dark grey. The structure of CedV-G is colored according to sequence conservation with NiV-G, identical residues are red and similar
residues are pink. Measles virus hemagglutinin (MeV-H) branch is truncated for illustrative purposes. Structures used for the analysis were the Ghanaian bat henipavirus
G (GhV-G; PDB 4UF7), Nipah virus G (NiV-G; PDB 2VWD), Hendra virus G (HeV-G; PDB 2X9M), CedV-G, MeV-H (PDB 2RKC), Mo`jiang virus G (MojV-G; PDB 5NOP), human
parainﬂuenza virus 3 hemagglutinin-neuraminidase (HPIV3-HN; PDB 1V3B), Newcastle disease virus HN (PDB 1E8T), parainﬂuenza virus 5 HN (PIV5-HN; PDB 4JF7), and
mumps virus HN (MuV-HN; PDB 5B2C). Branches of the resultant tree are labelled with the calculated evolutionary distances.
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Figure 2. Ephrin-B1 and ephrin-B2 bind CedV-G.
(A) Increasing concentrations of soluble ephrin-B–Fc (10−11 to 10−7 M) were added to HNV-G transfected HEK-293T cells and binding (measured as GMFI values) was
assessed by ﬂow cytometry using Alexa Fluor 647–labelled anti-human Fc antibodies. Four-parameter dose–response or logistic (4PL) curves were generated by
nonlinear regression using GraphPad Prism. Data from GMFI values are displayed as percent of maximal binding, with the maximal binding value at the highest
concentration of ligand used set to 100%. The bottom of each 4PL curve was constrained to have a constant value of zero. The reported Kd (dissociation constant)
corresponds to the ephrin ligand concentration [sEphrin-B3–Fc], at which 50% maximal binding is achieved. A value of N/A refers to data that could not be ﬁtted
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physiologically relevant cell type. Real-time quantitative PCR (qPCR)
analysis of B-class ephrin transcripts within primary HUVECs revealed
the presence of mRNA encoding both ephrin-B1 and ephrin-B2,
whereas ephrin-B3 mRNA was undetectable (Fig 4A). After conﬁr-
mation of active transcription of ephrin-B1 and ephrin-B2 in HUVECs,
soluble envelope competition assays were performed to assess
HNVpp entry (Fig 4B and C).
Preincubation of HUVECs with saturating quantities of sNiV-G–Fc
completely inhibited NiVpp entry, suggesting that all available cell
surface displayed ephrin-B2 molecules were sequestered by sol-
uble NiV-G and thus viral entry was not supported in the absence of
an alternate cognate receptor for NiV, namely, ephrin-B3. Con-
versely, under identical conditions, CedVpp entry was still sup-
ported at ~50%, evidencing ephrin-B1-mediated entry of CedVpp in
the absence of available ephrin-B2 (Fig 4B). Entry of both NiVpp and
CedVpp was completely abrogated by preincubation with soluble
Eph-B3 receptor (sEph-B3–Fc), an Eph receptor that binds to all
three B-class ephrin ligands with similar afﬁnities (53), further
conﬁrming that viral entry is ephrin-dependent (Fig 4C). These data
reveal that endogenously expressed ephrin-B1 supports CedVpp
entry in a physiologically relevant cell type, validating the role of
ephrin-B1 as a functional entry receptor for CedV.
The CedV-G–ephrin-B1 structure reveals a conserved HNV-
G–ephrin interaction mode
After our ﬁndings that CedV was able to use a previously unreported
receptor repertoire, we sought to delineate the molecular features
of ephrin binding and ligand selectivity. To this end, we solved the
crystal structure of the attachment-mediating β-propeller of CedV-
G in complex with the extracellular β-barrel domain of human
ephrin-B1, to 4.07-A˚ resolution. Five complexes populated the crys-
tallographic a.s.u. and displayed no appreciable structural variation,
within the limits of the resolution. Analyses herein concern the
complex comprising chains “B” and “D,” which was selected for su-
perior quality electron density and the model quality permitted as a
consequence (Fig S4).
Comparison with the unliganded structure of CedV-G reveals little
overall structural variation (0.4 A˚ RMSDover 417 equivalent Cα)within the
ephrin-B1–bound CedV-G scaffold. Notably, the β6-S2–S3 loop, which is
conformationally distinct in each of the unliganded CedV-G crystallo-
graphic a.s.u. copies (Fig 1A), is also the region of greatest structural
variability when comparing the ephrin-B1 bound and unbound states of
CedV-G. Structural plasticity within this region is observed in other HNV-
G proteins and their ephrin-bound complexes (39, 40).
Figure 3. Ectopic expression of ephrin-B1 or ephrin-
B2 is sufﬁcient to confer CedVpp entry into a non-
susceptible cell type.
(A, B, C, D) NiVpp, CedVpp, and BALDpp (VSV
pseudotypes bearing no viral glycoprotein) were
used to infect (A) CHO-pgsA745 cells (a naturally
ephrin-negative cell line) or CHO-pgsA745 cells that
stably express (B, C, D) ephrin-B1 (CHO-B1), ephrin-B2
(CHO-B2), or ephrin-B3 (CHO-B3), respectively, over a
range of viral inoculum (viral genomes/mL). Entry was
measured as described in the legend to Fig 2. The
asterisk indicates an RLU value above the maximum
limit of detection. RLU were plotted against numbers of
viral genome copies per milliliter and ﬁtted to a
linear regression (dashed lines) using GraphPad Prism.
Data shown are the averages of three independent
biological replicates ± SE.
unambiguously to a 4PL curve, that is, binding of soluble ephrin was not titratable or saturation could not be achieved even at concentrations up to 100 nM. Values for
ephrin-B3–Fc binding to GhV-G are not displayed, as no detectable binding over background was observed. Data shown are the averages of three independent biological
replicates ± SE. (B) NiV-F/G (NiVpp), HeV-F/G (HeVpp), GhV-F/G (GhVpp), and CedV-F/G (CedVpp) VSV-ΔG-rLuc pseudotyped viruses were used to infect Vero CCL81
cells in the presence of increasing amounts of soluble ephrin-B1–Fc, ephrin-B2–Fc, and ephrin-B3–Fc fusion proteins (10−12 to 10−8 M). 4PL curves were generated
using GraphPad Prism as above. Data from relative light unit(s) (RLU) values are displayed as percent of maximal infection, deﬁned as the RLU achieved in the
presence of media alone, which is set to 100%. The top and bottom of each 4PL curve was constrained to have a constant value of 100 and 0, respectively. Data
shown are the averages of three independent biological replicates ± SE.
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CedV-G engages ephrin-B1 with an overall binding mode that is
similar to that used by other HNV-G proteins, when recognizing their
respective ephrin receptors (Fig 5A–C) (26, 36, 48). CedV-G and ephrin-
B1 forma 1:1 complexwith an extensivemolecular interface that buries
a combined surface area of 2,900 A˚2 (1,450 A˚2 per component). The
buried interface is larger than that previously characterized for other
HNV-G–ephrin complexes (NiV-G–ephrin-B2 = 2,800 A˚2; NiV-G–ephrin-
B3 = 2,700 A˚2; HeV-G–ephrin-B2 = 2,600 A˚2; GhV-G–ephrin-B2 = 2,300 A˚2,
calculated using the PDBePISA server (54)). Ephrin-B1 is bound at the
top of the molecule and forms an interface that chieﬂy comprises
residues from the structurally conserved β4–6 blades of CedV-G,
which contribute ~70% (~2,000 A˚2) of the total buried surface area
(Figs 1, 5C, and S1). Despite localizing to the interface, the glycan at
N425 extends away from ephrin-B1 and does not appear to participate
in receptor binding.
Like the other HNV-G–ephrin complexes, the G–H loop of ephrin-
B1 (residues 113–129ephrin−B1) constitutes a major interacting region
and is inserted into the central depression on top of CedV-G,
contributing 1,700-A˚2 buried surface area to the molecular interface
(Fig 5A–C). Interestingly, despite sequence variation and pronounced
structural dissimilarity in their unliganded states (55), the G–H loops of
ephrin-B1 and ephrin-B2 adopt a strikingly similar conformation in
their HNV-G–bound states (Fig 5C). Indeed, the Greek-key fold of the
bound ephrin-B1 ectodomain is highly similar to that of NiV-G–bound
ephrin-B2 (1.0-A˚ RMSD across 135 aligned Cα atoms), although less
similar to ephrin-B3 (1.6 A˚ RMSD across 126 aligned Cα atoms). Dif-
ferences between the structural states of both CedV-G and ephrin-B1
may represent an induced-ﬁt mechanism of ephrin recognition, which
has been postulated for other ephrin-tropic HNVs (36, 39, 40), or
selection from a conformational equilibrium.
Ephrin-B1 and ephrin-B2 are bound by the same site on CedV-G
Given the striking structural similarities between CedV-G–ephrin-B1
and other HNV-G–ephrin complexes (Fig 5B), we hypothesized that
CedV-G likely uses the same receptor-binding site to engage ephrin-B2.
To assess this, we determined pseudotyped virus entry into CHO-B1
and CHO-B2 cells in the presence of competing soluble B-class
ephrin ligands. As expected (46, 56, 57), ephrin-B2–Fc and ephrin-
B3–Fc inhibited NiVpp entry into CHO-B2 cells, whereas ephrin-
B1–Fc failed to strongly inhibit entry at concentrations as high as 10
nM (Fig 5D, middle panel), conﬁrming that ephrin-B2 and ephrin-B3
are each bound by the same site on NiV-G (36, 48). Similarly, both
ephrin-B2–Fc and ephrin-B1–Fc inhibited CedVpp entry into CHO-B2
cells (Fig 5D, right panel), evidencing the ability of ephrin-B1 to
block ephrin-B2–dependent CedVpp entry through competition for
an overlapping binding site on CedV-G. Moreover, ephrin-B2–Fc
inhibited CedVpp entry into CHO-B1 cells (Fig 5D, left panel). In both
CHO-B2 and CHO-B1 cells, ephrin-B2–Fc–mediated inhibition of
CedV-G was more potent than ephrin-B1–Fc (Fig 5D), further sup-
porting our binding (Fig 2) and entry (Fig 3) data that suggest
ephrin-B2 is more efﬁciently used than ephrin-B1.
To further validate our hypothesis, we performed soluble envelope
competition assays inwhich CHO-B2 cells were incubatedwith soluble
NiV-G–Fc, before infection with NiVpp or CedVpp (Fig 5E, middle and
right panels, respectively). Entry of NiVpp and CedVpp on CHO-B2 cells
was completely inhibited by NiV-G–Fc, indicative that CedV-G and NiV-
G recognize a common interface on ephrin-B2, which, in conjunction
with the structures of CedV-G (Fig 1) and CedV-G–ephrin-B1 (Fig 5A–C),
supports a universal mode of ephrin recognition across ephrin-tropic
HNVs. Importantly, CedVpp entry into CHO-B1 cells was unaffected by
saturating amounts of NiV-G–Fc (Fig 5E, left panel). Thus, despite a
shared mode of receptor engagement across ephrin-tropic HNVs,
these data indicate that CedV-G possesses subtle but distinct features
within its receptor-binding site that determine utilization of its idi-
osyncratic receptor repertoire.
Accommodation of the YMmotif of ephrin-B1 is a key determinant
of receptor speciﬁcity
To determine the molecular features that underscore the distinct
ephrin speciﬁcity of CedV-G, we examined both the structural and
Figure 4. Ephrin-B1 facilitates CedVpp entry into biologically relevant primary HUVECs.
(A) Active transcription of ephrin-B1, ephrin-B2, and ephrin-B3 in primary HUVECs was determined by qPCR. Transcript levels are shown normalized to hypoxanthine
phosphoribosyltransferase (HPRT) transcripts. Ephrin-B3 transcript levels were below the limit of detection (asterisk). Data shown are the individual data points from two
independent biological replicates. Horizontal dashes represent the mean from the two replicates. (B, C) NiVpp, CedVpp, and VSVpp were used to infect primary HUVECs in
the presence of increasing amounts (10−9 to 10−7 M) of Fc-tagged (B) soluble NiV-G (sNiV-G–Fc) or (C) soluble Eph-B3 receptor (sEph-B3–Fc). Entry wasmeasured as in Fig
2. Data are shown as percent infection relative to the signal achieved when the viruses are incubated in the presence of media alone. Data shown are the individual data
points from two independent biological replicates. Dashed lines connect the means from the duplicate data. Statistical signiﬁcance for this entry inhibition assay was
tested with a two-way ANOVA with Holm-Sidak’s correction for multiple comparisons, n/s denotes no signiﬁcance, * denotes P < 0.05, ** denotes P < 0.005.
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Figure 5. CedV-G binds ephrin-B1 and ephrin-B2 at a conserved and overlapping binding site.
(A) The crystal structure of CedV-G in complex with ephrin-B1 reveals a conserved mode of receptor engagement across ephrin-tropic HNV-G proteins. The
receptor-binding domain of CedV-G (colored in a gradient from blue to red, from N- to C terminus) forms a 1:1 complex with the extracellular domain of ephrin-B1
(dark grey). The principal interaction region of ephrin-B1, the “G–H loop,” is displayed as a thick tube for clarity. Modelled N-linked glycan moieties (pink) and the
asparagine residues of all putative N-linked glycosylation sequons are shown as sticks. (B) Superposition of NiV-G–ephrin-B2 (PDB: 2VSM) on CedV-G–ephrin-B1.
The NiV-G–ephrin-B2 complex is colored in light grey, with NiV-G shown as transparent for clarity. (C) Comparison of bound ephrin-B1 and ephrin-B2 molecules.
CedV-G is shown as a white transparent surface with the ephrin-B1 interface colored according to sequence position as in panel (A). Regions of ephrin-B1 (dark grey)
and ephrin-B2 (light grey) bound by CedV-G and NiV-G, respectively, are shown as cartoon tubes. β-propeller blades are delineated with triangles that are colored
according to sequence position as in panel (A). (D) Ephrin-B1 and ephrin-B2 compete for binding to CedV-G. NiVpp and/or CedVpp were used to infect CHO-B2 cells
(middle and right panels) or CHO-B1 cells (left panel), as indicated, in the presence of increasing amounts of soluble ephrin-B1–, ephrin-B2–, and ephrin-B3–Fc
(10−12 to 10−8 M). Entry was measured as in Fig 2. 4PL dose–response curves were generated as in Fig 2 and based on values displayed as percentages of infection
with the RLU achieved in the presence of media alone set to 100%. The top of each ﬁt curve was constrained to a have a constant value of 100. Data shown are the
individual data points from two independent biological replicates with the ﬁt curves shown in dashed lines. (E) NiV-G and CedV-G compete for binding to ephrin-B2.
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functional implications of two hydrophobic motifs that differ between
ephrin-B1 and ephrin-B2. Although the G–H loops of B-type ephrin
paralogs are highly conserved (Fig 6A), ephrin-B1 and ephrin-B2 differ
by the presence of a Tyr121–Met122 (YM) or Leu121–Trp122 (LW)motif, which
have previously been shown to be critical determinants of differential
receptor utilization (46). Inspection of the CedV-G–ephrin-B1 complex
structure reveals that the side chain of Tyr121−ephrin-B1 is inserted into a
large hydrophobic cavity that is unique to CedV-G (Fig 6B and C). In-
deed, the equivalent region within NiV-G (Trp504), HeV-G (Trp504), and
GhV-G (Trp514) is, in all instances, occluded by a tryptophan side chain
that protrudes toward the toroidal axis of the β-propeller, rather than
being sequestered in the opposing direction as is the equivalent
residue, Tyr525−CedV-G (Fig 6C). Thus, it is likely that the expanded hy-
drophobic cavity of CedV-G is critical to ephrin-B1 recognition as it
circumvents steric clashes that would preclude its recognition by other
HNV-Gs.
To interrogate this structure-based hypothesis, we tested
pseudotyped viral entry into CHO-pgsA745 cells stably expressing a
panel of wild-type and mutant ephrin ligands (Fig 6D). These stable
cell lines had been previously demonstrated to express similar
levels of the indicated wild-type and mutant ephrin ligands, as
measured by sEph-B3–Fc binding (46). As anticipated, NiVpp and
CedVpp were able to enter cells expressing ephrin-B2WT, whereas
ephrin-B1WT supported only CedVpp entry. Replacement of the
ephrin-B2 LW motif with the equivalent YM residues of ephrin-B1
(ephrin-B2YM) severely impaired the ability of ephrin-B2YM to
support NiVpp entry, although did not prevent it entirely. Con-
versely, the reciprocal exchange of the YM to LW motif in ephrin-B1
(ephrin-B1LW) rendered it capable of supporting some level of NiV
entry. Intriguingly, ephrin-B1LW–mediated entry of CedVpp was
increased relative to ephrin-B1WT, suggestive that the YM motif is
less efﬁciently used than LW for CedV entry, in the context of an
ephrin-B1 background. By contrast, introduction of the YM motif
into ephrin-B2 induced no appreciable difference in its ability to
support CedVpp entry. The differential response to the YM/LW
motifs, when presented in the context of distinct ephrin back-
grounds, highlights the importance of the myriad surrounding
interactions that comprise the extensive protein–protein interface.
Taken together, this integrated structural and functional analysis
suggests that the ability of CedV-G to effectively accommodate the
YMmotif of ephrin-B1, in a sterically unrestrained cavity, is a critical
determinant that directs ephrin-B1 utilization.
Discussion
Viral surveillance continues to revise the known geographic cov-
erage and biological diversity of HNV species (12). Although the
identiﬁcation of HeV and NiV was a consequence of their emer-
gence as the etiological agents of severe respiratory and neuro-
logical disease, targeted virus discovery efforts have demonstrated
utility in identifying novel HNVs yet to be linked with symptomatic
illness (10, 11, 19). One such virus, CedV, represents only the third
HNV species to be isolated and remains the sole member of the
genus conﬁrmed as nonpathogenic (19). Combined, the starkly
contrasting virulence and the ecological and biological similarities
between CedV and the deadly HNVs demarcates CedV as a valuable
model with which to assess HNV functional diversity and the de-
terminants of pathogenesis.
Through adoption of a combined structural and functional ap-
proach, we sought to determine the receptor repertoire used by
CedV-G and uncover molecular features that dictate its speciﬁcity.
We demonstrate that CedV-G uses a structurally constrained
receptor-binding architecture to mediate recognition of highly
conserved ephrin receptors using an analysis that relates local
structural conservation to discrete regions that are functionally
constrained amongst genetically diverse HNVs (Fig 1C). By dem-
onstrating ephrin-B2–mediated cellular entry of CedV, we conﬁrm
previous studies (19, 35) and provide evidence for a conserved
receptor recognition mode (Fig 5). Unexpectedly, we detected high
afﬁnity binding to ephrin-B1, a B-class ephrin with no precedent of
supporting HNV entry (Figs 2 and 3) and demonstrate that the
interaction is sufﬁcient to permit viral entry into pathobiologically
relevant primary endothelial cells (Fig 4). Furthermore, we present
crystal structures of CedV-G, in both unbound and ephrin-B1–
bound states (Figs 1 and 5), which reveal a common mode of
receptor recognition across distinct B-type ephrin ligands and
diverse HNV-G proteins.
The bipartite nature of structural conservation within CedV-G (Fig
1C) is indicative of contrasting selective pressures which, in blades
β1–β3 permit diversiﬁcation, but in the β4–β6 blades, constrain
variation to maintain high-afﬁnity ephrin binding. Like NiV and HeV,
CedV uses ephrin-B2 more efﬁciently than its cognate alternate
receptor, ephrin-B1 (or ephrin-B3 for NiV and HeV) (Figs 2 and 3)
(36, 46). Furthermore, despite its idiosyncratic receptor repertoire,
structure-based phylogenetic analysis co-localizes CedV-G with
other ephrin-tropic HNV-Gs, all of which are uniﬁed in using ephrin-
B2 for cellular entry (Fig 1D). Combined, the more effective ephrin-
B2 usage and structure-based phylogenetic association of all
ephrin-tropic HNV-Gs implicate ephrin-B2 as a receptor used by
ancestral HNVs, alongside which coincident alternate receptor
speciﬁcities may have arisen.
Despite evident commonalities of HNV-G–mediated ephrin rec-
ognition, the structure of CedV-G–ephrin-B1 reveals unique molec-
ular properties that provide a structure-based rationale for receptor
speciﬁcity. Modulation of the side chain orientation of a single amino
acid in CedV-G (Y525) relieves a steric barrier that likely precludes
ephrin-B1 recognition by other HNV-Gs. Given that only minor
changes to ephrin-B1 are required for it to support NiV entry (Fig 6D)
(46), and the existence of relatively subtle structural differences
within HNV-G receptor-binding sites, it is possible that the existence
or acquisition of ephrin-B1 tropism in extant HNVs may not be
uncommon. Although the molecular features that preclude ephrin-
B3 utilization by CedV-G remain unclear, our structural hypothesis
NiVpp or CedVpp were used to infect CHO-B2 (middle and right panels) or CHO-B1 (left panel) cells in the presence of increasing amounts of soluble Fc-tagged
NiV-G (sNiV-G–Fc) (10−10 to 10−7 M). Data are shown as percent infection relative to the signal achieved when the viruses were incubated in the presence of media
alone. Data shown are the averages of three independent biological replicates ± SE.
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suggests that acquired ephrin-B1 speciﬁcity does not necessarily
come at the expense of ephrin-B3 usage, as the LWmotif is common
to both ephrin-B2 and ephrin-B3.
The acquisition of alternate receptor speciﬁcities, and the
species and cell type tropism thereby engendered, is of acute
biomedical and agricultural importance (27). For example, the
systemic dissemination and multi-organ vasculitis associated with
NiV and HeV is consistent with expression of ephrin-B2 in endo-
thelial cells (56, 58) and peripheral organs, such as the kidney, lung,
and spleen, wherein ephrin-B3 is less abundant. However, central
nervous system disease pathologies (59, 60), which are the ultimate
cause of death in fatal NiV and HeV infection, are likely a conse-
quence of markedly increased and speciﬁc expression of ephrin-B3
in multiple brain regions (Fig S5) (61, 62, 63).
Although the absence of IFN antagonism in CedV likely plays a
critical role in determining its apathogenic phenotype (19, 20), an
inability to use ephrin-B3may also be a contributing factor. Interestingly,
although ephrin-B1 is expressed at low to negligible levels in the
central nervous system, its expression in other tissues is both more
widespread and often greater in magnitude than ephrin-B2. Of note
is the relatively high expression of ephrin-B1 in the lung, esoph-
agus, and salivary glands (Fig S5), which suggests that ephrin-B1
utilization could augment aspects of oropharyngeal transmission
postulated for HNVs (64), especially because ephrin-B1 is almost as
conserved as ephrin-B2 across mammalian species (96–99% se-
quence similarity). Thus, although the pathobiological and eco-
logical implications of ephrin-B1 tropism are presently unclear, our
study sets a precedent for ephrin-B1 utilization and in so doing
expands the known repertoire of HNV cellular entry receptors used
by this group of lethal human pathogens. Whilst the preprint
version of this article was under peer-review (65 Preprint), Laing
et al reported similar results (66).
Finally, in light of our structure–function analyses, it is plausible
that the barrier for ephrin-B1 usage may not be high, and that other
Figure 6. Accommodating the YM motif is critical for ephrin-B1 utilization by CedV.
(A) Sequence alignment of the G–H loop region of human B-type ephrins. Absolutely conserved residues are highlighted red, partially conserved residues are colored
red, and non-conserved residues are black. Residues that constitute the YM/LW motif are outlined with a black box. Sequences are numbered according to ephrin-B1.
Alignments were determined by MultAlin (80) and plotted using ESPript (81). (B) Structure of CedV-G–ephrin-B1. CedV-G is displayed as a white surface with the ephrin-B1
interface colored according to the sequence position (blue to red, N- to C terminus). The principal interacting region of ephrin-B1 is shown as a dark grey cartoon tube,
with the side chains of Y121 and M122, the “YM motif,” shown as sticks and colored according to constituent atoms. (C) Detailed view of the YM motif of ephrin-B1 (boxed
region in a; middle) and the equivalent view of the LW motif of NiV-G–bound ephrin-B2 (light grey; top). (bottom) Overlay of the NiV-G residue, W504 (red) onto CedV-
G–ephrin-B1, demonstrates potential steric overlap between NiV-G and ephrin-B1. The side chain of Y525 in CedV-G is sequestered away from the receptor-binding site.
Side chains of key residues are shown as sticks and colored according to constituent atoms. (D) CedV is more tolerant to substitution of the YM/LW motif than NiV. CHO
cells expressing both wild-type ephrins (B1 and B2) and mutants with reciprocally exchanged LW/YM motifs (B1LW and B2YM) were infected with NiVpp (top) or CedVpp
(bottom). Entry was assessed and quantiﬁed as in Fig 2. Data represent the average of quadruplicate measurements ± SE. Statistical signiﬁcance for the indicated
comparisons were evaluated using a two-tailed unpaired t test, ** denotes P < 0.005 and n/s denotes no signiﬁcance.
Unique ephrin-tropism of Cedar virus Pryce et al. https://doi.org/10.26508/lsa.201900578 vol 3 | no 1 | e201900578 10 of 15
HNVs may acquire, or have already acquired, an expanded rep-
ertoire of B-class ephrin receptors that could modulate pathoge-
nicity and transmissibility. Characterization of receptor tropism
characteristics should be central to future surveillance efforts that
aim to identify and assess new HNVs, to elucidate the association
between pathogenicity and expanded receptor usage.
Materials and Methods
Protein production
Independent expression vectors for the putative six-bladed β-pro-
pellerdomain of CedV-G (residues 209–622; National Center for Bio-
technology Information [NCBI] reference sequence: YP_009094086.1)
and the G-interacting N-terminal extracellular domain of ephrin-B1
(residues 29–167; NCBI reference sequence NP_004420.1) were gen-
erated by PCR ampliﬁcation from codon-optimized synthetic cDNA
templates (GeneArt; Life Technologies) and subsequent restriction-
based cloning into the pHLsec mammalian expression vector (67).
HEK-293T cells (American Type Culture Collection CRL-1573) were
transiently transfected with the desired protein constructs and
expressed in the presence of the class 1 α-mannosidase inhibitor,
kifunensine (68). For the generation of CedV-G–ephrin-B1 com-
plexes, cells were co-transfected with a 1:1.5 mass ratio of CedV-G to
ephrin-B1 cDNA. Cell supernatants were harvested and clariﬁed 72 h
posttransfection, after which supernatants were diaﬁltrated against
a buffer containing 10 mM Tris (pH 8.0) and 150 mM NaCl (A¨KTA Flux
diaﬁltration system; GE Healthcare). In all instances, glycoproteins
and their complexes were puriﬁed by a tandem immobilized nickel
afﬁnity and size exclusion chromatography strategy using HisTrap
HP and Superdex increase 200 10/300 GL columns (GE Healthcare),
equilibrated in 10mM Tris (pH 8.0) and 150mMNaCl, respectively. To
aid crystallogenesis of unliganded CedV-G, high-mannose–type
N-linked glycans were trimmed by partial enzymatic deglycosyla-
tion with endoglycosidase F1 (25°C for 18 h).
For the production of Fc-tagged HNV-G proteins used in cellular
assays, codon-optimized DNA fragments corresponding to the
receptor-binding domains of NiV-G (residues 183–602; NCBI ref-
erence sequence: NC_002728.1) and CedV-G (residues 209–622; NCBI
reference sequence: YP_009094086.1) were cloned into the pHL-
FcHis vector (67). Transfection and protein puriﬁcation procedures
were identical to those used for the production of non-Fc–tagged
proteins, detailed above. In all instances, kifunensine was not
present during the expression of HNV-G–Fc.
Crystallization and structure determination
Endoglycosidase F1–treated CedV-G was concentrated to 6.7 mg/ml
and subjected to room temperature crystallization screening using
the sitting-drop vapor diffusion method (69). A single crystal of
CedV-G was observed after 15 d in a condition comprising 5% (wt/
vol) polyethylene glycol 6000 and 0.1 M MES pH 6.0. In addition,
CedV-G–ephrin-B1 containing high-mannose glycans derived from
expression in the presence of kifunensine was concentrated to 12.2
mg/ml. Crystals formed after 132 d in a condition comprising 25%
polyethylene glycol 1500 (wt/vol), 0.1 M PCB (sodium propionate,
sodium cacodylate, and BIS-TRIS propane) pH 5.0 and 0.02 M
cadmium chloride dihydrate (70).
Crystals were harvested and cryoprotected by transfer into a drop
of the respective mother liquor supplemented with 25% glycerol (vol/
vol) before ﬂash cooling in liquid nitrogen. X-ray diffraction data were
collected for CedV-G (to 2.78-A˚ resolution) and CedV-G–ephrin-B1 (to
4.07-A˚ resolution) at beamlines I02 and I24 at Diamond Light Source
(UK), respectively. Crystal data were indexed, integrated, and scaled
using XIA2 (71). The structure of CedV-G was solved by molecular
replacement, implemented in PHASER (72), using the structure of
unliganded NiV-G (PDB accession code 2VWD) as a search model. The
structures of CedV-G (reported here) and ephrin-B2 (derived from the
NiV-G–ephrin-B2 complex [PDB: 2VSM]), were used as independent
search models to solve the structure of CedV-G–ephrin-B1. In both
instances, iterative rounds of model building and reﬁnement were
performed using COOT (73), PHENIX (74), and REFMAC (75), using
non-crystallographic symmetry restraints and translation/libration/
screw parameterization. The structure of CedV-G–ephrin-B1 was re-
ﬁned using grouped B-factors and reference model restraints derived
from the higher resolution CedV-G structure. Conformational vali-
dation of N-linked glycans was performed using Privateer (76). Data
collection and reﬁnement statistics are presented in Table S1.
Structure-based phylogenetic analysis
Available structures of unique paramyxovirus receptor-binding
glycoproteins (G/H/HN) were used to construct a structure-based
phylogenetic tree. Structures used were as follows: human para-
inﬂuenza virus 3, HPIV3-HN (PDB accession code: 1V3B) (77); Newcastle
disease virus, NDV-HN (1E8T) (78); parainﬂuenza virus 5, PIV5-HN (4JF7)
(43); mumps virus, MuV-HN (5B2C) (79); Ghana virus, GhV-G (4UF7) (26);
Nipah virus, NiV-G (2VWD) (39); Hendra virus, HeV-G (2X9M) (40); Cedar
virus, CedV-G; measles virus, MeV-H (2RKC); and Mo`jiang virus, MojV-G
(5NOP) (18). A pairwise evolutionary distance matrix was calculated
using the Structural Homology Program (37) and plotted as an
unrooted phylogenetic tree using PHYLIP (38).
Cells and culture conditions
HEK-293T, Vero-CCL81, and U87 (American Type Culture Collection
HTB-14) cells were grown in DMEM supplemented with 10% FBS and
1% penicillin/streptomycin (Thermo Fisher Scientiﬁc). Previously
described CHO-pgsA745 cells expressing either wild-type or mutant
ephrins (46) were maintained in DMEM/F12 medium (Thermo Fisher
Scientiﬁc) with 10% FBS and 1% penicillin/streptomycin. HUVECs
(pooled donors; Lonza) were maintained in EndoGRO-LS Complete
Media Kit, composed of EndoGRO Basal Medium and the EndoGRO
Supplement Kit (Millipore Sigma). EndGRO medium was also sup-
plemented with 2% FBS, 1% penicillin/streptomycin, and 1% GlutaMAX
supplement (Thermo Fisher Scientiﬁc). HUVECs used for soluble en-
velope competition experiments were between passage three and six.
Plasmids and reagents
Codon-optimized sequences of CedV-G (GenBank accession number
AJP33320.1) and CedV-F (GenBank accession number YP_009094085.1)
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were tagged with a C-terminal HA or AU1, respectively, and cloned into
pCAGGSmammalian expression vectors, as previously described for
extant HNV glycoproteins (26, 47). Soluble human ephrin-B1–Fc,
ephrin-B2–Fc, ephrin-B3–Fc, and Eph-B3–Fc used for competition
experiments were purchased from R&D Systems.
Cell surface binding assay
Binding of soluble Fc-tagged human ephrin-B ligands to HNV-G–
transfected cells was assessed by ﬂow cytometry. HEK-293T cells
were transfected, using Lipofectamine 2000 (Thermo Fisher Sci-
entiﬁc), with equal concentrations of plasmids encoding the in-
dicated HNV-G proteins, or an empty vector control. Transfected
cells were subsequently double-stained with a primary rabbit anti-
HA polyclonal antibody (pAb) (Cat. no. NB600-363; Novus) at a 1:
1,000 dilution, as well as increasing amounts of the ephrin-B1–Fc,
ephrin-B2–Fc, and ephrin-B3–Fc ligands for 1 h at 4°C. Cells were
then washed with buffer (2% FBS/PBS) and incubated with an
Alexa488–labelled goat anti-rabbit antibody (Cat. no. A-11034;
Thermo Fisher Scientiﬁc) diluted 1:2,000, to identify HNV-G positive
cells, and an Alexa647–labelled goat anti-human antibody (Cat. no.
A-21445; Thermo Fisher Scientiﬁc) diluted 1:2,000, to capture ephrin–B
binding, for 1 h at 4°C. Cells were washed in 2% FBS/PBS, ﬁxed in
2% PFA/PBS, and subjected to ﬂow cytometry (Guava easyCyte).
Data were analyzed using FlowJo v10 software. Binding curves
were generated by ﬁrst gating on the live, HA-positive (i.e., HNV-G
positive) population. The geometric mean ﬂuorescence intensity
(GMFI) in the red channel of this gated, G-positive population
quantiﬁed the level of ephrin-B ligand binding. The highest GMFI
value obtained within each dilution series was normalized to 100%,
and cell surface Kd values were calculated using GraphPad Prism.
Pseudotyped virus
VSV particles pseudotyped with the HNV surface glycoproteins
(HNVpp) were produced as previously described (26, 47, 56). Brieﬂy,
the particles were made from a VSV-ΔG-rLuc virus, a recombinant
VSV derived from a full-length cDNA clone of the VSV Indiana
serotype in which the VSV-G envelope protein is replaced by Renilla
Luc. Pseudotyping was accomplished by transfecting HEK-293T cells
(using BioT; Bioland Scientiﬁc) with expression plasmids containing
the codon-optimized C-terminally tagged F and G envelope glyco-
proteins of NiV (NiVpp), HeV (HeVpp), GhV (GhVpp), CedV (CedVpp), or
the VSV-G glycoprotein itself (VSVpp), and then infecting with VSV-ΔG-
rLuc (complemented with VSV-G). Pseudotype-containing media were
clariﬁed 48 h after infection, by centrifugation at 200g for 5 min.
Supernatants were then loaded on a 20% sucrose cushion and subject
to ultra-centrifugation for 3 h at 110,000g. Concentrated pseudo-
particle pellets were then resuspended in Dulbecco’s PBS and stored
at −80°C.
Incorporation of henipaviral glycoproteins into HNVpp
Incorporation of F and G glycoproteins within NiVpp and CedVpp
was determined by western blotting. Both F and G were detected
using tag-speciﬁc anti-AU1 and anti-HA antibodies, respectively.
Dilutions of NiVpp, CedVpp, and BALDpp (VSV virions bearing no
glycoprotein) were lysed in 6× Laemmli buffer (5% β-mercaptoethanol
ﬁnal), boiled for 10 min, and separated on an Any kD Mini-PROTEAN
TGX Precast Protein Gel before transfer to a polyvinylidene diﬂuoride
(PVDF) membrane. Membranes were stained with a primary rabbit
anti-HA pAb (Cat. no. NB600-363; Novus), diluted 1:2,000, and a primary
rabbit anti-AU1 pAb (Cat. no. NB600-453; Novus), diluted 1:2,000. The
membranes were then washed in PBS supplemented with 0.1%
Tween-20 and incubated with Alexa647-labelled goat antirabbit an-
tibody (Cat. no. A-21245; Thermo Fisher Scientiﬁc), diluted 1:4,000. To
control for loading, the membranes were also stained for VSV matrix
protein using a primary mouse anti-VSV-M mAb (Cat. no. EB0011;
Kerafast), diluted 1:1,1000, and a secondary Alexa647-labelled goat
anti-mouse antibody (Cat. no. A-21236; Thermo Fisher Scientiﬁc), di-
luted 1:3,000. Membranes were imaged using a Bio-Rad ChemiDoc and
densitometry analysis was performed by using the Bio-Rad Image Lab
5.1 software.
Quantiﬁcation of viral genome copies
Viral RNA was extracted from HNVpp preparations using the QIAamp
viral RNA Mini Kit (QIAGEN) and subsequently reverse-transcribed
using the Tetro cDNA Synthesis Kit (Bioline). VSV genome copy
number was quantiﬁed by qPCR, using the SensiFAST SYBR &
Fluorescein kit (Bioline), using genome-speciﬁc primers against the
VSV Indiana L region (sequences available on request). Standard
curves were generated by a serial dilution of the full-length VSV-
ΔG-rLuc genomic plasmid.
Quantiﬁcation of viral entry
Target cells were grown in 96-well plates and infected with the
pseudoviruses serially diluted in appropriate cell culture medium.
For soluble ephrin-B entry inhibition experiments, the indicated
amounts of soluble ephrin-B–Fc (R&D Systems) were incubated
together with a pseudotyped virus for 1 h at 37°C. The mixture
of virus and soluble ephrin-B was then added to the target cells.
For soluble envelope entry inhibition experiments, the indicated
quantity of soluble HNV-G–Fc (production described above) or
soluble Eph-B3–Fc (R&D Systems) were incubated with the ad-
herent target cells for 1 h at 37°C. After incubation with soluble
protein, pseudotyped virus was added. To assess viral entry into the
wild-type and mutant ephrin-expressing cell lines (Fig 6D),
equivalent amounts of NiVpp and CedVpp (titrated to give roughly
equivalent rLuc activities on CHO-B2 cells) were used to infect the
distinct ephrin-expressing CHO-pgsA745 cell lines.
In all instances, the quantity of pseudotyped virus stock used was
predetermined to fall within the linear dynamic range of Renilla Luc
detection. Furthermore, in all HNVpp entry experiments, infected cells
were washed with PBS and lysed 24 h postinfection. Cell lysates were
subsequently processed using a Renilla Luciferase Detection Kit,
according to the manufacturer’s directions (Promega). Luminescence
intensity was measured using a Cytation3 Plate Reader.
Quantiﬁcation of ephrin-B mRNA transcripts in primary HUVECs
Ephrin-B1, -B2, and -B3 mRNA transcripts present in the primary
HUVECs were quantiﬁed using qPCR. Total RNA was extracted from
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3 × 105 HUVECs with a NucleoSpin RNA isolation kit (Macherey-Nagel).
ProcessedmRNA transcriptswere reverse-transcribed into cDNAusing
oligo(dT) primers and the Tetro cDNA synthesis kit (Bioline). qPCR was
performed using the SensiFAST SYBR & Fluorescein Kit (Bioline), using
gene-speciﬁc primers (sequences available on request) for ephrin-B1,
-B2, and -B3. Standard curves for each genewere generated by a serial
dilution of the ephrin-B pcDNA3.1 expression plasmids. As a nor-
malization control, hypoxanthine phosphoribosyltransferase (HPRT)
copy numbers were also determined.
HNV glycoprotein-mediated syncytia formation in U87
glioblastoma cells
Syncytia assays were performed by transfecting U87 cells with HNV-F
and HNV-G expression plasmids or an empty vector control (using
Lipofectamine 2000; Thermo Fisher Scientiﬁc). Bright-ﬁeld images
were taken at 48 hposttransfectionwith aNikon Eclipse TE300Diaphot
Microscope. Images represent two random ﬁelds for each condition.
Data deposition
The atomic coordinates and structure factors for CedV-G and CedV-
G–ephrin-B1 have been deposited in the PDB with the accession
codes 6THB and 6THG, respectively.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900578.
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